Cell Reprogramming-based Therapies for Liver Disease

A large number of patients worldwide are affected by liver dysfunction. Creative Bioarray is committed to helping customers develop new cell therapies to more effectively treat liver diseases through cell reprogramming technologies. We are confident to provide you with efficient and professional technical support to accelerate your research in new therapies development.


The increasing incidence of liver disease has accelerated research into new therapeutic approaches such as transplantation of mature liver cells. Difficulties in obtaining sufficient numbers of fully functional hepatocytes and poor implantation in the host liver of thawed and cryopreserved hepatocytes have limited the widespread use of this therapy in the treatment of liver disease. Currently, researchers are focusing on differentiating iPSC into hepatocyte-like cells (HLC) or reprogramming somatic cells into functional hepatocytes to serve as a replacement for human hepatocytes. Reprogrammed cells are considered a promising and unlimited source of hepatocytes, and this strategy could provide a powerful tool to produce enough HLCs to treat patients with acute liver failure (ALF), metabolic diseases, or patients not being considered for organ transplantation.

Fig 1. Typical protocol for iPSCs reprogramming and hepatic differentiation of human into hepatocyte-like cells in vitro.Fig.1 Typical protocol for iPSCs reprogramming and hepatic differentiation of human into hepatocyte-like cells in vitro. (Zhang, 2021)

Development of New Therapies for Liver Disease based on Cell Reprogramming

Researchers at Creative Bioarray have focused on different strategies for reprogramming somatic cells to the pluripotency, their differentiation to HLCs and applying them to provide cell-based therapies for liver disease in two major areas:

  • The manufacture of unlimited numbers of HLCs available to extend therapies to many patients.
  • The use of autologous genetically corrected HLCs for the treatment of inherited liver diseases.

Critical Steps for Developing New Therapies Using iPS-derived Cells

For the development of therapies using iPSC-derived HLC for the treatment of liver disease, several key steps need to be considered from the acquisition of iPSC to their eventual use in patients with metabolic or other liver diseases. We provide customers with a series of preclinical research services from cell reprogramming to safety assessment.

Fig 2. Key steps for therapeutic application of iPS-derived cells. (Creative Bioarray)Fig.2 Key steps for therapeutic application of iPS-derived cells.


To help our clients develop effective cellular therapies and advance the translation to clinical application, we offer solutions for the following issues:

  • Immunogenicity of HLCs derived from iPSCs
  • Tumorigenicity and safety of gene editing
  • Engraftment of transplanted cells
  • Large-scale production of HLCs


  • Innovative research teams
  • Advanced cell reprogramming and disease modeling technologies
  • Extensive experience in the field of gene editing
  • Multiple evaluation systems for the effectiveness of new therapies

Equipped with professional laboratory equipment and technical staff with good scientific knowledge, Creative Bioarray provides systematic and holistic solutions for the development of new therapies for liver diseases based on cell reprogramming. If you have research needs in related fields, please contact us for more details.


  1. Zhang, L.; et al. The application of induced pluripotent stem cells against liver diseases: An update and a review. Frontiers in Medicine. 2021, 8.
For Research Use Only. Not For Clinical Use.